BiotechTube

Saizen® solution for injection (referred as Saizen®)

ApprovedCompleted
1 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Adult Growth Hormone Deficiency

Conditions

Adult Growth Hormone Deficiency

Trial Timeline

Jun 1, 2013 → Mar 1, 2016

NCT ID
NCT01806298

About Saizen® solution for injection (referred as Saizen®)

Saizen® solution for injection (referred as Saizen®) is a approved stage product being developed by Merck for Adult Growth Hormone Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT01806298. Target conditions include Adult Growth Hormone Deficiency.

What happened to similar drugs?

8 of 20 similar drugs in Adult Growth Hormone Deficiency were approved

Approved (8) Terminated (3) Active (11)
✅BenralizumabAstraZenecaApproved
✅FluMist + inactivated influenza vaccineAstraZenecaApproved
✅Tacrolimus/Sirolimus + Tacrolimus/MMF + Neoral/SirolimusRocheApproved
✅Aztreonam lysineGilead SciencesApproved
✅maraviroc + Raltegravir + Darunavir/ritonavirPfizerApproved
✅SabrilLundbeckApproved
✅NaCl 0.9% in Glucose 5% with 40mEq Potassium + Glucion 5%BaxterApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01806298ApprovedCompleted

Competing Products

20 competing products in Adult Growth Hormone Deficiency

See all competitors
ProductCompanyStageHype Score
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
Daridorexant + PlaceboIdorsiaPhase 1
23
SON-1010 (IL12-FHAB)Sonnet BioTherapeuticsPhase 1
23
SomatropinEli LillyPhase 3
40
agenT-797MiNK TherapeuticsPhase 1
19
PegilodecakinEli LillyPhase 1
29
eFT226 + Sotorasib + Fulvestrant + Abemaciclib + TrastuzumabeFFECTOR TherapeuticsPhase 1/2
29
Lazertinib(G001) + Lazertinib(G002)YuhanPhase 1
29
Patritumab deruxtecanDaiichi SankyoPhase 2
27
DJ-927 + capecitabineDaiichi SankyoPhase 1
29
Valemetostat TosylateDaiichi SankyoPhase 2
35
RoxadustatAstellas PharmaPhase 1
29
ASP3325 + PlaceboAstellas PharmaPhase 1
29
TRK-100STPAstellas PharmaPhase 1
29
EnsitrelvirShionogiPhase 1
29
E6130 + PlaceboEisaiPhase 1
29
E7389 + E7389 + E7389EisaiPhase 1
29
Eribulin MesylateEisaiPhase 1
29
E2022 + E2022 + E2022 + E2022 + E2022EisaiPhase 1
29
Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil Hydrochloride + Donepezil HydrochlorideEisaiPhase 1
29